CRP and non-small cell lung carcinoma: CRP decrease 6 weeks post-treatment initiation was associated with PFS and OS benefit in patients treated with atezolizumab in second-line NSCLC, even in patients whose tumors appeared unchanged by RECIST 1.1 (SD patients) at six weeks.